Analysts report strong sentiments about
Genmab A S Depositary Receipt stock due to its high-performance investment picks and
strong DARZALEX® sales for Q2 2025. Several investment firms, including
Truist Securities and
UBS, have raised the company’s stock price target due to strong revenue outlook. The company has attracted attention by announcing the results of its
EPCORE NHL-2 Trial and employee warrant exercise initiative. In spite of its fluctuating performance in previous years, recent disclosures about managerial share transactions and impressive Q1 2025 slides showing 19% revenue growth suggest an upward trend. Although its partnership with
J&J on HexaBody-CD38 encountered roadblocks, other developments like the launch of a share buy-back program indicate optimism. The company also experienced notable pressures in the form of a lawsuit by AbbVie and varying stock ratings among different banks.
Genmab Stocks News Analytics from Wed, 03 Apr 2024 07:00:00 GMT to Sat, 19 Jul 2025 05:04:49 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 2
